礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09637 礼邦医药-B

未开盘 08-20 16:09:07

33.340

+0.160

+0.48%

最高35.460	最低33.000	成交量28.73万
今开33.000	昨收33.180	日振幅7.41%
总市值116.02亿	流通市值78.68亿	总股本3.48亿
成交额993.56万	换手率0.12%	流通股本2.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"礼邦医药-B","latestPrice":33.34,"timestamp":1787213347879,"preClose":33.18,"halted":0,"volume":287285,"delay":0,"changeRate":0.0048221820373720225,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"未开盘","change":0.16,"latestTime":"08-20 16:09:07","open":33,"high":35.46,"low":33,"amount":9935571,"amplitude":0.074141,"askPrice":33.34,"askSize":1800,"bidPrice":33.32,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-2.384,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":0,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":33.18,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":1.0704523340651269,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09637","defaultTab":"news","newsList":[{"id":"1198136493","title":"礼邦医药-B（09637）临时股东会通过审计师委任及股份发行、回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1198136493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198136493?lang=zh_cn&edition=full","pubTime":"2026-08-14 18:22","pubTimestamp":1786702925,"startTime":"0","endTime":"0","summary":"8月14日，礼邦医药-B公布其于2026年8月14日举行的临时股东会投票结果，全部议案均获股东高票通过。此次会议共有348,365,531股具表决权股份获准参与投票，公司董事会成员全部以现场或电子方式出席会议。公告同时披露，截至EGM召开日，公司无任何库存股份或待注销的回购股份，亦不存在股东受限投票或需放弃投票的情形。截至公告日，礼邦医药-B董事会由4名执行董事、1名非执行董事及3名独立非执行董事组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178604628","title":"礼邦医药-B（09637）董事会定于2026年8月26日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178604628","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178604628?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:42","pubTimestamp":1786621361,"startTime":"0","endTime":"0","summary":"礼邦医药-B（09637）8月13日公告称，公司董事会将于2026年8月26日（星期三）召开会议，届时将审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜。公告显示，截至公告日期，公司董事会由8名成员组成，包括4名执行董事──Gavin Guoyao Xia博士、Jin Tian医生、汪昀女士及张华丁博士；1名非执行董事鲁安博士；以及3名独立非执行董事徐润红博士、Zhui Chen博士及梁智维先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135560","title":"【券商聚焦】华泰证券首予礼邦医药（09637）买入评级 指肾病管线卡位优","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135560","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659135560?lang=zh_cn&edition=full","pubTime":"2026-08-13 13:52","pubTimestamp":1786600358,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发布研报指，首次覆盖礼邦医药-B 并给予“买入”评级，目标价51.86港元。据CIC数据，2025年全球高磷血症药物市场规模达18亿美元，2035年有望达64亿美元，且全球仅有这两个创新管线。2023年公司与罗氏达成独家商业化合作，华泰预计美信罗有望于2034年在中国实现约10亿元人民币销售峰值，考虑中国长效制剂渗透率提升、成熟商业化团队支撑以及罗氏供应瓶颈解决。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","159938","09637","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132620884","title":"礼邦医药-B（09637）高磷血症新药AP301获国家药监局受理上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1132620884","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132620884?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:30","pubTimestamp":1786095045,"startTime":"0","endTime":"0","summary":"2026年8月7日，礼邦医药-B发布自愿公告称，公司自主研发的口服含铁磷结合剂AP301胶囊用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请已获中国国家药品监督管理局正式受理。该申请基于在中国完成的关键III期临床试验RESPOND-1结果及其他临床数据。RESPOND-1试验在中国50家中心开展，共入组474名高磷血症透析患者，按3:1随机分配至AP301组和阳性对照药碳酸司维拉姆组，治疗周期52周。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657011619","title":"礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657011619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657011619?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:26","pubTimestamp":1786094817,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1161","09939","BK1574","09637","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108879461","title":"礼邦医药-B发布2026年中期盈利预喜：收入同比大增逾7倍，亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1108879461","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108879461?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:42","pubTimestamp":1786005722,"startTime":"0","endTime":"0","summary":"礼邦医药（江苏）股份有限公司8月6日公告称，根据董事会对截至2026年6月30日止六个月未经审阅的合并管理账目初步评估，预期本期收入约为1.03亿元至1.06亿元，较去年同期的12.1百万元增长约750%至775%。董事会表示，收入大幅增长主要源于AP306与R1 Therapeutics签订许可及股权协议确认的许可收入，以及美信罗销售增加；亏损收窄则受益于上市前若干股份赎回责任终止，报告期内不再计提相关利息。公司计划于2026年8月公布中期业绩。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161461460","title":"礼邦医药-B发布2026年7月股份变动月报，H股注册股本增至2.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161461460","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161461460?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:48","pubTimestamp":1785919721,"startTime":"0","endTime":"0","summary":"礼邦医药(江蘇)股份有限公司于2026年8月5日公布截至2026年7月31日的股份变动月报。报告期内，公司H股注册股本由2.27亿元增至2.36亿元，增加8,513,300股；内资股保持不变，维持1.13亿元。截至本月末，公司注册股本合计达3.48亿元，较上月增长约8,513,300股。本报告期内，公司因于2026年7月29日悉数行使超额配股权而完成相应H股增发，发行价格为每股22.6港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519476","title":"港股异动 | FSGS赛道热度再起，礼邦医药-B(09637)大涨超15% 机构指其有望进入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657519476?lang=zh_cn&edition=full","pubTime":"2026-08-05 15:51","pubTimestamp":1785916293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月5日，礼邦医药-B大幅走高，盘中涨超15%。截至发稿，涨13.07%，报33.22港元，成交额2921.2万港元。今年4月，FILSPARI获FDA批准成为首个FSGS治疗药物，这一长期缺药的肾病适应症正被资本市场重新定价。FSGS的热度也让市场重新审视礼邦医药在同一适应症上的布局。该行测算，49只股票有望纳入港股通，其中包括礼邦医药。据悉，获纳入港股通有利于扩大公司投资者基础，潜在提高H股交易流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","KCAI","FSGS","159938","BK1191","VXUS","FLHK","BK4585","09939","BK1574","09637","BK1515","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657194215","title":"港股异动 | FSGS赛道热度再起，礼邦医药-B(09637.HK)大涨超15% 机构指其有望进入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2657194215","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657194215?lang=zh_cn&edition=full","pubTime":"2026-08-05 15:51","pubTimestamp":1785916293,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1574","09637","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656329615","title":"港股异动 | 礼邦医药-B(09637)涨超6% 近日AP306全球多区域IIb期临床试验完成首例受试者随机入组并给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2656329615","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656329615?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:26","pubTimestamp":1785742008,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B涨超6%，截至发稿，涨6.68%，报29.06港元，成交额468.56万港元。消息面上，近日，据礼邦医药官微消息，公司宣布其同类首创口服泛磷转运蛋白抑制剂AP306用于接受维持性血液透析的高磷血症患者的全球 IIb 期多区域临床试验已完成首例受试者随机入组并给药。与主要结合肠道游离磷的传统磷结合剂不同，AP306通过广泛抑制NaPi-IIb、PiT-1和 PiT-2三种关键肠道磷转运蛋白，减少肠道对磷的主动转运，为高磷血症管理探索差异化治疗路径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","IBBJ","BK4588","159938","09637","BK1191","BMED","MDTX","BK1161","BK1515","BK4585","IBBQ","09939","VXUS","PSYK","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101811485","title":"礼邦医药-B（09637）完成超额配股权行使　注册资本增至3.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101811485","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101811485?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:12","pubTimestamp":1785330753,"startTime":"0","endTime":"0","summary":"2026年7月29日，礼邦医药-B公告称，因全球发售项下8,513,300股H股的超额配股权已被悉数行使，公司注册资本及股份总数相应变更，并已修订公司章程相关条款。超额配股权行使完成后，公司注册资本由人民币339,852,231元上调至人民币348,365,531元；公司股份总数同步由339,852,231股增至348,365,531股，全部为人民币普通股。根据2025年10月30日股东会授予的授权及董事会的进一步授权，董事会授权人士已批准就全球发售完成情况对公司章程进行上述调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139138224","title":"礼邦医药-B：7月29日行使超额配股权发行约851.33万股H股，涉资约1.92亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139138224","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139138224?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:31","pubTimestamp":1785317508,"startTime":"0","endTime":"0","summary":"礼邦医药(江苏)股份有限公司（礼邦医药-B，股票代码：09637）于2026年7月29日发布翌日披露报表，宣布因全额行使超额配股权发行并配发H股。根据公告资料，本次发行总计8,513,300股H股，相当于该次发行前公司已发行股本（227,122,189股）的3.75%。\n本次发行的每股价格为22.6港元，共涉及资金约1.92亿港元。完成发行后，公司已发行股本增加至235,635,489股。本次发行已获得礼邦医药(江苏)股份有限公司董事会正式授权，符合香港联合交易所有限公司证券上市规则及相关法律法规的要求和规定。\n本公告由礼邦医药(江苏)股份有限公司联席公司秘书陈南佑签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼邦医药-B：7月29日行使超额配股权发行约851.33万股H股，涉资约1.92亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655863629","title":"礼邦医药-B(09637)因超额配股权获行使而发行851.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655863629","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655863629?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:23","pubTimestamp":1785317006,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B(09637)发布公告，于2026年7月29日根据悉数行使超额配股权而发行及配发的H股股份851.33万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159938","BK1191","09939","BK1574","09637","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128705724","title":"礼邦医药-B发布临时股东会通告 将审议20%增发及10%回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1128705724","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128705724?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:26","pubTimestamp":1784903176,"startTime":"0","endTime":"0","summary":"2026年7月24日，礼邦医药-B公告称，公司拟于2026年8月14日举行临时股东会，地点为中国上海市黄浦区淮海中路283号香港广场南座1206室303会议室，会议时间为上午十时正。会议将审议一项普通决议案及两项特别决议案。普通决议案方面，公司拟委任安永会计师事务所为新核数师，任期自临时股东会通过决议之日起至公司下届年度股东会结束时止，并授权董事会决定其酬金。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179614591","title":"礼邦医药-B拟回购不超过已发行股份10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179614591","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179614591?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:26","pubTimestamp":1784903171,"startTime":"0","endTime":"0","summary":"礼邦医药（江苏）股份有限公司于近日发布公告称，公司拟在即将举行的临时股东大会上提呈特别决议案，授予董事会一般性授权，从而在香港联合交易所有限公司可回购不超过公司在临时股东大会通过相关决议当日已发行H股总数10%的股份。根据公告披露，公司目前已发行股份总数为339,852,231股，包括227,122,189股H股及112,730,042股非上市股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"礼邦医药-B拟回购不超过已发行股份10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133223988","title":"礼邦医药-B（09637）超额配股权悉数获行使 额外募资约1.85亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133223988","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133223988?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:37","pubTimestamp":1784882236,"startTime":"0","endTime":"0","summary":"2026年7月24日，礼邦医药（江苏）股份有限公司公告称，联席代表已全数行使全球发售项下的超额配股权，涉及8,513,300股H股，占超额配股权获行使前全球发售可供认购股份总数约15%。公司因本次超额配股权行使额外获得的净募资约为1.85亿港元。在超额配股权悉数行使及稳定价格期结束后，礼邦医药-B继续符合上市规则第19A.13A条所规定的公众持股量要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653707427","title":"礼邦医药-B(09637.HK)：悉数行使超额配股权、稳定价格行动及稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2653707427","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653707427?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:33","pubTimestamp":1784882032,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","BK1515","09939","BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653426297","title":"Tencent Holdings Limited增持礼邦医药(09637)23.85万股 每股作价约27.97港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653426297","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653426297?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806238,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月17日，Tencent Holdings Limited增持礼邦医药(09637)23.85万股，每股作价27.9667港元，总金额约为667.01万港元。减持后最新持股数目约为2291.62万股，最新持股比例为10.09%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK4504","BK4550","EWH","09637","BK4588","EDZ","BK1191","BK1161","BK1515","159938","BK1574","BK4585","IEMG","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105801707","title":"礼邦医药-B（09637）AP306全球IIb期试验完成首例受试者随机给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1105801707","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105801707?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:01","pubTimestamp":1784635318,"startTime":"0","endTime":"0","summary":"2026年7月21日，礼邦医药-B发布自愿公告称，其用于治疗接受维持性血液透析患者高磷血症的同类首创口服泛磷转运蛋白抑制剂AP306全球IIb期多区域临床试验已完成首例受试者的随机化并给药。该试验正在美国及中国的多家临床中心同步开展。2024年6月，中国国家药品监督管理局已授予AP306突破性疗法认定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653721742","title":"礼邦医药-B(09637)：AP306治疗接受维持性血液透析患者高磷血症的全球IIb期多区域临床试验完成首例受试者随机化并给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653721742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653721742?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:00","pubTimestamp":1784635233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，AP306用于接受维持性血液透析的高磷血症患者的全球IIb期多区域临床试验已完成首例受试者随机化入组并给药。IIb期试验是一项多中心、随机、双盲、安慰剂对照研究，旨在评估固定剂量 AP306用于接受维持性血液透析的高磷血症患者的安全性、耐受性及降低血清磷的效果。IIb期试验计划招募约168名受试者，并将其随机分配至AP306六个固定剂量方案组或安慰剂组，治疗期为八周。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","BK1161","09939","IBBJ","BK1515","IBBQ","BK1191","159938","BK1574","MDTX","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alebund.com","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":0.1433},{"period":"3month","weight":0.4752},{"period":"ytd","weight":0.4752}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0271},{"period":"1year","weight":0.0212},{"period":"ytd","weight":0.0027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"礼邦医药（江苏）股份有限公司是一家主要从事生物制药的中国公司。该公司的临床及临床前产品组合由一款核心产品AP301及其他候选产品组成，包括：一款临床后期候选产品（AP306）、一款临床前期候选药物（AP303），以及四款临床前候选药物（AP308、AP304、AP305与AP307）。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"礼邦医药-B","nameEN":"ALEBUND-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼邦医药-B,09637,礼邦医药-B股票,礼邦医药-B股票老虎,礼邦医药-B股票老虎国际,礼邦医药-B行情,礼邦医药-B股票行情,礼邦医药-B股价,礼邦医药-B股市,礼邦医药-B股票价格,礼邦医药-B股票交易,礼邦医药-B股票购买,礼邦医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}